ATM抑制通过激活STING信号和增强MHC I类增强免疫疗法
Chunya Li1, Boyu Wang2, Jingyao Tu1
1Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Cell death & disease
|July 20, 2024
概括
向DNA损伤反应 (DDR) 通过ATAXIA telangiectasia突变 (ATM) 抑制可以增强抗瘤免疫力. 抑制ATM可以提高结肠直肠癌 (CRC) 细胞的免疫反应,预测放射治疗和免疫治疗的益处.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 针对DNA损伤反应 (DDR) 的向疗法在增强抗瘤免疫力方面表现有前途.
- 突变的telangiectasia (ATM) 是一种关键的DNA修复蛋白质,在各种癌症中具有显著的突变率,但在免疫疗法中尚未研究.
- 结肠直肠癌 (CRC) 提供了一个探索新型DDR向治疗策略的机会.
研究的目的:
- 研究ATM抑制在调节结直肠癌中瘤免疫微环境中的作用.
- 阐明ATM抑制诱导的免疫反应背后的分子机制.
- 确定ATM准作为CRC中联合放射治疗和免疫治疗的预测生物标志物的潜力.
主要方法:
- 利用基因淘汰和药理抑制剂来准结直肠癌细胞中的ATM.
- 评估了cGAS/STING和NFκB/IRF1/NLRC5通道的激活情况.
- 在临床前癌症模型中评估了MHC I类表达和T细胞反应.
- 在接受放射治疗和免疫检查点封锁的患者中,与临床结果相关的ATM突变.
主要成果:
- 通过基因淘汰或药物治疗,ATM抑制激活了cGAS/STING通路,并在CRC细胞中调节了MHC I类.
- 放射治疗增强了ATM抑制对免疫反应的影响.
- MHC I 类上调取决于NFκB/IRF1/NLRC5 途径,独立于STING.
- 在动物模型中,ATM缺乏的瘤表现出增强的T细胞透,细胞毒性功能和改善的生存率.
- 在CRC患者中,ATM无意义突变预测了放射治疗与免疫检查点阻塞相结合的良好反应.
结论:
- ATM抑制是一种可行的策略,可以增强结直肠癌的抗瘤免疫力.
- 在NFκB/IRF1/NLRC5路径中介ATM抑制诱导的MHC类I上调.
- ATM状态作为结合模式癌症治疗的预测生物标志物.
- 针对ATM的疗法有可能改善CRC患者的治疗结果.
相关概念视频
Tumor Immunotherapy
504
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
504
T Cell Activation and Clonal Selection
696
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
696
Antigens Involved in Adaptive Immunity
482
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
482
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Cell-mediated Immune Responses
68.0K
Overview
68.0K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K


